Abstract
Limitations of early drug-eluting stents (DESs) such as late stent thrombosis and evidence of delayed neointimal healing have prompted the development of DESs with new platform materials, thinner stent struts, more-biocompatible or more-biodegradable surface polymer coatings, and less-potent antiproliferative drugs. However, in the manufacturer-funded SORT OUT III trial, risks for both definite stent thrombosis and target-vessel revascularization (TVR) were significantly …
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
